Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Dupilumab in Children With Moderate to Severe Atopic Dermatitis
NCT06461897Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Aug 2024; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06461897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461897.